BRAF and non-small cell lung carcinoma: PD-L1 expression was assessed in 163 patients diagnosed with BRAF-mutant NSCLC, which included 43 from the treatment cohort and 120 with characterized immune profiles (detailed PD-L1 levels for each patient were depicted in Supplementary Table 3).